MedTrace Logo

Incentives for Moving

NCT01278680 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2015-08-19

No results posted yet for this study

Summary

Employees of Blue Shield of California (BSC) will be recruited to participate to regularly use Walkstations. Some participants will be randomly assigned to a "hold out" control condition and the remainder will be assigned to one of two experimental treatments: Personal Incentive vs. Charitable Incentive. In the Personal Incentive condition people will be paid $3 for every completed Walkstation session, whereas for participants in the Charitable Incentive condition $3 will be donated to a specific charity. The incentives will operate for approximately 45 days and then for an additional 45 days participants in the two experimental conditions will have access to the Walkstations. Participants in the hold out control condition will begin using the Walkstations after the initial 90 day period.

Conditions

  • Sedentary Lifestyle; Obesity; General Well-being

Interventions

BEHAVIORAL

Incentives for walkstation usage

The investigators are testing the effect of two different incentive schemes on people's usage of walkstations at work: either a personal incentive (in which people receive personal financial benefit for using the walkstations) vs. a charitable incentive (in which others receive financial benefit if a given individual uses the walkstation).

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01278680 on ClinicalTrials.gov